HIV-1 reservoirs

Clinics in Laboratory Medicine

Volumn 22, Issue 3, 2002, Pages 651-680

  Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS DETECTION; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY; VIRUS REPLICATION;

EID: 0036716956     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00005-7     Document Type: Review

References (149)

1. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
2. Prognosis in HIV infection predicted by the quantity of virus in plasma
3. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
4. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
6. A controlled trial of two nucleoside analogous plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
7. HIV-1 in the semen of men receiving highly active anti-retroviral therapy
8. AIDS other diseases due to HIV infection
9. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
10. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
11. Detection of HIV-1 DNA and RNA in individual cells by PCR-driven in situ hybridization and flow cytometry
12. Single cell transcript analysis of human immunodeficiency virus gene expression in the transition from latent to production infection
13. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4
14. Detection of AIDS virus in macrophages in brain tissue from AIDS patients
15. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
16. Progression to the Glb phase of the cell cycle is required for completion of human immunodeficiency virus type I reverse transcription in T cells
17. Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: An important stage for viral infection of nondividing cells
18. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life-cycle
19. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection
20. HIV-1 replication is controlled at the level of T cell activation and proviral integration
21. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro
22. HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28
23. Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation
24. Loss of inducible virus in CD45RA naive cells, after human immunodeficiency virus-I entry accounts for preferential viral replication in CD45RO memory cells
25. Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type I strain LAI
26. Highly purified CD25- resting T cells cannot be infected de novo, with HIV-1
27. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type I-infected individuals
28. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells
29. Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency
30. Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency
31. Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns
32. Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1
33. Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection
34. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort
35. Decay characteristics of HIV-1-infected compartments during combination therapy
36. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
37. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
38. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy
39. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy
40. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection
41. Induction of HIV-1 replication in latently infected CD4+ T-cells using a combination of cytokines
42. In vitro reactivation of human immunodeficiency virus I from latently infected, resting CD4+ T-cells after bacterial stimulation
43. A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children
44. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection
45. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
46. HIV replication in macrophages isolated from HIV-infected patients receiving protease inhibitors
47. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy
48. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1
49. CD45RC isoforms define two types of CD4 memory T cells, one of which depends on persisting antigen
50. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men
51. Lymph node architecture preceding and following 6 months of potent antiviral therapy: Follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient
52. Gastrointestinal tract as a major site of CD4+ T-cell depletion and viral replication in SIV infection
53. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis
54. HIV-1 is detectable in mucosal biopsies in patients with undetectable plasma viral loads
55. Monocytes harbour replication-competent non-latent HIV-1 in patients on highly active antiretroviral therapy
56. Residual HIV-1 infection during antiretroviral therapy: The challenge of viral persistence
57. Relationship between pre-existing viral reservoirs and the re-emergency of plasma viremia after discontinuation of highly active anti-retroviral therapy
58. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent anti-retroviral therapy
59. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals
60. Phenotype associated sequence variation in the third variable region of the human immunodeficiency virus type 1 gp120 molecule
61. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection
62. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection
63. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission
64. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral and vertical transmission
65. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
66. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of beta-chemokines
67. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: Characteristics and natural history of the virus
68. Transmission of zidovudine-resistant HIV during a bloody fight
69. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts
70. HIV-1 drug resistance in newly infected individuals
71. Reduced antiretroviral drug susceptibility among patients with primary HIV-infection
72. Prevalence of HIV-1 resistance to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
73. Primary HIV-1 resistance: A new phase in the epidemic?
74. Analysis of HIV-1 load in blood, semen and saliva: Evidence for different viral compartments in a cross-sectional and longitudinal study
75. Infection of the retina by human immunodeficiency virus type 1
76. Pathogenesis of infection with human immunodeficiency virus
77. The kidney is a previously unrecognized reservoir for HIV-1 replication
78. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
79. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
80. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex
81. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and Efavirenz: Drug concentrations in HIV-1-infected patients receiving combination therapy
82. Indinavir-based treatment of HIV-1-infected patients: Efficacy in the central nervous system
83. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir
84. HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid
85. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir
86. Poor penetration of the male genital tract by HIV-1 protease inhibitors
87. HIV-1 replication in patients with undetectable plasma virus receiving HAART
88. Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active anti-retroviral therapy (HAART)
89. Nucleoside analogues achieve high concentrations in seminal plasma: Relationship between drug concentration and virus burden
90. Quantification of HIV in semen: Correlation with antiviral treatment and immune status
91. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen
92. Potent anti-retroviral treatment of HIV infection results in suppression of the seminal shedding of HIV
93. Effect of antiviral treatment on the shedding of HIV-1 in semen
94. Effect of antiretroviral therapy on HIV shedding in semen
95. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA
96. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy
97. Viral load and heterosexual transmission of human immunodeficiency virus type 1
98. HIV-1 shedding pattern in semen correlates with the compartmentalization of viral quasispecies between blood and semen
99. Sites of productive infection of HIV in the male GU tract
100. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
101. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
102. Human immunodeficiency virus type I genetic evolution in patients with prolonged depression of plasma viremia
103. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
104. Infectious HIV-1 derived from PBMC coculture reflects a subset of transcriptionally active variants present in PBMC in patients with prolonged suppression of plasma viremia with HAART
105. Persistent vRNA in PBMC from HIV-infected patients on potent antiretroviral therapy is associated with rare vRNA + cells
106. Decay rates of cellassociated HIV-1 DNA correlate with residual viral replication in patients treated during primary HIV-1 infection
107. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy
108. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells
109. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1 infected subjects in the absence or presence of effective therapy
110. HIV-1 latent reservoirs renewed by viral replication in activated CD4+ T lymphocytes, monocytes, and resting CD4+ T lymphocytes in patients receiving potent therapy
111. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes
112. Reverse transcription takes place within extracellular HIV-1 virions: Potential biological significance
113. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: Direct assessment of resistance to reverse transcriptase inhibitors in vivo
114. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies per milliliter
115. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
116. Suppression of plasma viral load below 20 copies per milliliter is required to achieve a long term response to therapy
117. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy
118. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation
119. Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy
120. Early therapy of vertical HIV-1 infection: Evidence for cessation of viral replication and absence of virus-specific immunity
121. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
122. Rebound of plasma HIV viral load following prolonged suppression with combination therapy
123. Control of HIV despite the discontinuation of antiretroviral therapy
124. Persistence of intracellular HIV-1 mRNA (in-cell viral load) correlates with HIV-specific immune responses in HIV-infected subjects on stable HAART therapy
125. Human immunodeficiency virus type I quasispecies that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral species present before initiation of therapy
126. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy
127. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report
128. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection
129. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
130. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
131. Constant mean viral copy number per infected cell in tissues regardless of high, low or undetectable plasma HIV RNA
132. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors
133. Antiretroviral drugs and the central nervous system
134. Relationship between pre-existing latent viral reservoirs and the re-emergence of plasma viremia following discontinuation of highly active antiretroviral therapy
135. Dissociation of HIV-1 from follicular dendritic cells during HAART: Mathematical analysis
136. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: Partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia
137. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2
138. Ongoing HIV dissemination during HAART
139. Antigendriven CD4+ T-cell and HIV-1 dynamics: Residual viral replication under highly active antiretroviral therapy
140. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1 even inpatients on effective combination therapy
141. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy
142. Chimeric toxins targeted to the human immunodeficiency virus type I envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-hu mice
143. Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies per milliliter of HIV-RNA and >500 X 106/gl CD4 cells treated with highly active anti-retroviral therapy
144. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
145. The natural history and clinical significance of intermittent virological "blips" in patients who attain an initially undetectable viral load (VL) on HAART
146. The significance of low-level viremia in patients with previously "undetectable" HIV-1 RNA levels
147. Biphasic decay of latent HIV-1 in resting CD4+ T cells in acute seroconverters
148. Selection of antiretroviral resistance in the latent reservoir of human immunodeficiency virus type 1 during successful therapy
149. Human immunodeficiency virus type I-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups